vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Commercial Vehicle Group, Inc. (CVGI). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $154.8M, roughly 1.2× Commercial Vehicle Group, Inc.). On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -5.2%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $8.7M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -10.8%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
AMPH vs CVGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $154.8M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 9.7% |
| Operating Margin | 19.4% | -1.2% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | -5.2% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $154.8M | ||
| Q3 25 | $191.8M | $152.5M | ||
| Q2 25 | $174.4M | $172.0M | ||
| Q1 25 | $170.5M | $169.8M | ||
| Q4 24 | $186.5M | $163.3M | ||
| Q3 24 | $191.2M | $171.8M | ||
| Q2 24 | $182.4M | $193.7M | ||
| Q1 24 | $171.8M | $194.6M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-7.1M | ||
| Q2 25 | $31.0M | $-4.8M | ||
| Q1 25 | $25.3M | $-4.3M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $9.5M | ||
| Q2 24 | $37.9M | $-1.6M | ||
| Q1 24 | $43.2M | $2.9M |
| Q4 25 | 46.8% | 9.7% | ||
| Q3 25 | 51.4% | 10.5% | ||
| Q2 25 | 49.6% | 11.4% | ||
| Q1 25 | 50.0% | 10.5% | ||
| Q4 24 | 46.5% | 8.0% | ||
| Q3 24 | 53.3% | 9.6% | ||
| Q2 24 | 52.2% | 10.6% | ||
| Q1 24 | 52.4% | 11.9% |
| Q4 25 | 19.4% | -1.2% | ||
| Q3 25 | 13.2% | -0.7% | ||
| Q2 25 | 24.2% | 0.5% | ||
| Q1 25 | 21.9% | 0.8% | ||
| Q4 24 | 24.2% | -3.2% | ||
| Q3 24 | 29.8% | -0.6% | ||
| Q2 24 | 30.3% | 0.5% | ||
| Q1 24 | 27.9% | 2.3% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -4.6% | ||
| Q2 25 | 17.8% | -2.8% | ||
| Q1 25 | 14.8% | -2.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 5.5% | ||
| Q2 24 | 20.8% | -0.8% | ||
| Q1 24 | 25.1% | 1.5% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | $-0.05 | ||
| Q1 24 | $0.81 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $104.9M |
| Stockholders' EquityBook value | $788.8M | $133.4M |
| Total Assets | $1.6B | $391.7M |
| Debt / EquityLower = less leverage | 0.77× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $104.9M | ||
| Q3 25 | $608.6M | $108.2M | ||
| Q2 25 | $607.7M | $118.2M | ||
| Q1 25 | $603.9M | $117.4M | ||
| Q4 24 | $601.6M | $135.5M | ||
| Q3 24 | $596.4M | $128.8M | ||
| Q2 24 | $586.9M | $142.0M | ||
| Q1 24 | $594.0M | $155.7M |
| Q4 25 | $788.8M | $133.4M | ||
| Q3 25 | $776.7M | $136.5M | ||
| Q2 25 | $757.5M | $142.6M | ||
| Q1 25 | $751.3M | $136.7M | ||
| Q4 24 | $732.3M | $135.6M | ||
| Q3 24 | $727.7M | $179.3M | ||
| Q2 24 | $713.3M | $169.6M | ||
| Q1 24 | $672.4M | $175.5M |
| Q4 25 | $1.6B | $391.7M | ||
| Q3 25 | $1.7B | $400.3M | ||
| Q2 25 | $1.6B | $429.8M | ||
| Q1 25 | $1.6B | $419.8M | ||
| Q4 24 | $1.6B | $424.6M | ||
| Q3 24 | $1.5B | $495.3M | ||
| Q2 24 | $1.5B | $503.2M | ||
| Q1 24 | $1.6B | $509.2M |
| Q4 25 | 0.77× | 0.79× | ||
| Q3 25 | 0.78× | 0.79× | ||
| Q2 25 | 0.80× | 0.83× | ||
| Q1 25 | 0.80× | 0.86× | ||
| Q4 24 | 0.82× | 1.00× | ||
| Q3 24 | 0.82× | 0.72× | ||
| Q2 24 | 0.82× | 0.84× | ||
| Q1 24 | 0.88× | 0.89× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $12.3M |
| Free Cash FlowOCF − Capex | $24.6M | $8.7M |
| FCF MarginFCF / Revenue | 13.4% | 5.6% |
| Capex IntensityCapex / Revenue | 4.5% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $34.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $12.3M | ||
| Q3 25 | $52.6M | $-1.7M | ||
| Q2 25 | $35.6M | $18.9M | ||
| Q1 25 | $35.1M | $15.2M | ||
| Q4 24 | $29.0M | $-26.6M | ||
| Q3 24 | $60.0M | $-17.1M | ||
| Q2 24 | $69.1M | $12.6M | ||
| Q1 24 | $55.3M | $-2.4M |
| Q4 25 | $24.6M | $8.7M | ||
| Q3 25 | $47.2M | $-3.5M | ||
| Q2 25 | $25.0M | $17.4M | ||
| Q1 25 | $24.4M | $11.4M | ||
| Q4 24 | $16.6M | $-30.6M | ||
| Q3 24 | $46.2M | $-20.3M | ||
| Q2 24 | $63.1M | $6.4M | ||
| Q1 24 | $46.5M | $-7.4M |
| Q4 25 | 13.4% | 5.6% | ||
| Q3 25 | 24.6% | -2.3% | ||
| Q2 25 | 14.3% | 10.1% | ||
| Q1 25 | 14.3% | 6.7% | ||
| Q4 24 | 8.9% | -18.7% | ||
| Q3 24 | 24.1% | -11.8% | ||
| Q2 24 | 34.6% | 3.3% | ||
| Q1 24 | 27.1% | -3.8% |
| Q4 25 | 4.5% | 2.3% | ||
| Q3 25 | 2.8% | 1.2% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 2.4% | ||
| Q3 24 | 7.2% | 1.9% | ||
| Q2 24 | 3.3% | 3.2% | ||
| Q1 24 | 5.1% | 2.6% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | -1.79× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | -0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
